Stratification and therapeutic potential of PML in metastatic breast cancer
Citations Over TimeTop 10% of 2016 papers
Abstract
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.
Related Papers
- → Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker(2014)26 cited
- → Ovarian cancer metastatic to the breast(2006)23 cited
- → 281 Quantitative Assessment of Her-2 Expression of Circulating Tumor Cells in Patients with Metastatic and Non Metastatic Breast Cancer(2012)
- Presence of circulating tumor cells bodes ill in metastatic breast cancer(2010)
- → Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy(2022)